Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Abaloparatide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Eladynos contains the active substance abaloparatide. It is used to treat osteoporosis in women after menopause. Osteoporosis is especially common in women after menopause. The disease causes bones to become thin and fragile. If you have osteoporosis, you are more likely to break bones, especially in your spine, hips and wrists. This medicine is used to make bone stronger and less likely to break. 2.
e Eladynos
Do not use Eladynos if you • are allergic to abaloparatide or any of the other ingredients of this medicine (listed in section 6) • are pregnant or breast-feeding • are still able to get pregnant • have high blood calcium levels • have severely reduced kidney function • have unexplained high blood levels of the enzyme alkaline phosphatase • have had radiation therapy involving your bones
2
•
have ever been diagnosed with bone cancer or other cancers that have spread to your bones
Warnings and precautions Talk to your doctor or pharmacist before or while using Eladynos if you: • get dizzy when standing up, which may be because of a fall in blood pressure. Some patients may get dizzy or have a fast heartbeat within 4 hours after Eladynos has been injected. The first injection/injections should be performed under the guidance of a health care professional who may observe you during the first hour after injection. Always inject Eladynos in a location where you can sit or lie down right away if you get dizzy. • have heart disease or high blood pressure. Your doctor may want to monitor you more closely. • have continuing nausea, vomiting, constipation, low energy or muscle weakness. These may be signs of too much calcium in your blood. • have high level of calcium in the urine, have or have had kidney stones. Eladynos may worsen your condition. Before you begin treatment with Eladynos your blood pressure and condition of your heart will be examined. The recommended treatment time of 18 months should not be exceeded. Children and adolescents Eladynos should not be used in children and adolescents under 18 years. Other medicines and Eladynos Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Especially tell your doctor or pharmacist if you take: • digoxin or digitalis: medicines used to treat heart weakness, as the levels of calcium in your blood may increase with use of abaloparatide • medicines to control high blood pressure, as they may worsen symptoms of low blood pressure, including dizziness Pregnancy and breast-feeding Do not use Eladynos if you are pregnant, may become pregnant or are breast-feeding. Driving and using machines Some patients may feel dizzy after injecting this medicine. If you feel dizzy do not drive or use machines until you feel better. Eladynos contains sodium This medicine contains less than 1 mmol sodium (23 milligrams) per dose, that is to say essentially "sodium-free". 3.
How to use Eladynos
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
3
The recommended dose is one injection (80 micrograms) once daily under the skin in the lower abdomen (belly). See grey shaded area of the first figure in Step 5 in the "Instructions for use" at the end of the package leaflet. Preferably, inject Elyadynos at the same time each day to help you remember to use your medicine. Do not inject Eladynos in the same place on your belly on consecutive days. Change where you inject this medicine each day to reduce the risk of injection site reactions. Only inject into clear skin. Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks. Please carefully follow the "Instructions for use" at the end of the package leaflet. Your doctor may advise you to take supplementary calcium and vitamin D. Your doctor will tell you how much you should take each day. Duration of use Inject Eladynos each day for as long as prescribed by your doctor. The maximum total duration of treatment with Eladynos should not exceed 18 months. If you use more Eladynos than you should If you accidentally use more Eladynos than you should, contact your doctor or pharmacist. The effects of overdose that might be expected include nausea, vomiting, dizziness (especially when getting up quickly), faster heartbeat and headache. If you forget to use Eladynos If you miss a dose, use it as soon as possible within 12 hours of the normally scheduled time. Then inject your next dose the usual time next day. If it is more than 12 hours since you should have used Eladynos, skip the missed dose. Then inject your next dose as usual on your next scheduled day. Do not use a double dose to make up for a forgotten dose. Do not use more than one injection in the same day. If you stop using Eladynos Discuss this with your doctor before stopping treatment. Your doctor will advise you and decide how long you should be treated with Eladynos. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
the Eladynos pen. DO NOT start the administration procedure until you have read the package leaflet and this instructions for use contained in your Eladynos carton thoroughly. Follow the instructions carefully whenever using the Eladynos pen. Contact your doctor, nurse or pharmacist if you have any questions about how to use the Eladynos pen. Important information before using your Eladynos pen • Do not share needles with other people. You may transmit a serious infection. Never share your Eladynos pen, even if the needle has been changed. • Use a new needle for each injection. Supplies you will need for each injection using your Eladynos pen • 1 needle Needles are not included with your Eladynos pen. The correct needles to use with your Eladynos pen are 8 mm, 31-gauge needles. • 1 alcohol swab • 1 cotton ball or gauze pad • 1 sharps disposal container for needles and Eladynos pens. See Section 5 of the Package leaflet for disposal information.
7
Parts of the Eladynos Pen Green injection button
Pen cap
Dose display window
Medicine cartridge holder
Dose knob
Lot / EXP
Plunger
Septum Medicine cartridge
Parts of the needle (not included with pen) to use with your pen Protective paper Needle
Outer needle cap
Inner needle cap
Inner needle
Injecting Eladynos
Step 1 Check the Eladynos pen Wash your hands. Check the pen label to make sure it is the correct medicine. Check the expiry date (EXP) on the pen to make sure it has not passed. EXP
Note the date of Day 1 to ensure you do not use the pen for more than 30 consecutive days.
8
Pull off the pen cap from your pen.
Check that the pen, including the medicine cartridge is not damaged. The liquid should be clear, colourless and free of particles; if not, do not use. You may see small air bubbles in the liquid. This is normal. Step 2 Attach needle to your Eladynos pen Remove the protective paper from a new needle.
Push the capped needle straight onto the pen and twist until it is secure. Make sure the needle is straight so that it doesn't bend when inserting. The pen will not work if the needle is not properly attached. Do not overtighten as this may make the needle difficult to remove. If the needle becomes bent, see below under "Troubleshooting".
Pull off the outer needle cap from the needle and keep it to use after your injection.
9
Carefully pull off the inner needle cap and dispose of it.
Step 3 Day 1 Only – Testing an Eladynos pen prior to first injection Your pen has medicine for 30 days, plus a small amount to test each pen once to confirm it is working properly. Attention: If you test the pen before every injection your pen will run out of medicine early. Therefore, perform Step 3 only on Day 1, prior to the first injection with each pen. For Day 2 through Day 30 do not test the pen again; go directly to Step 4 to set the dose for your injection. Holding the pen as illustrated, turn the dose knob on your pen away from you until it stops. You will see "•80" lined up in the dose display window.
Hold the pen with the needle pointing up. Press the green injection button until it will not go any further. You should see liquid, as a drop or stream, come from the needle tip.
10
You should see "●0" lined up in the dose display window. Note: If liquid does not come from the needle tip, see under "Troubleshooting"
Step 4 Set the dose on your Eladynos pen Turn the white knob on your pen away from you until the knob stops and "●80" is lined up in the display window. Your pen is now ready for injection.
Note: If you cannot set the pen to "●80", see below under "Troubleshooting". Step 5 Choose and clean your injection site Injections should be given in the lower abdomen as shown by the grey shaded area. Avoid the 5 cm area around your belly button.
11
Select a different injection site on your abdomen each day. Only inject into clear skin. Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks. Wipe the injection site with an alcohol swab and allow it to dry. Do not touch, fan or blow on the injection site after you have cleaned it.
Note: Your doctor, nurse or pharmacist may recommend that you pinch up the skin at the injection site. Once the needle enters the skin, the pinch can be released. Step 6 Giving your Eladynos pen injection Insert the needle straight into your skin.
Press and HOLD the green button until ALL events below are complete • "●0" is displayed • hold for 10 seconds to give full dose • withdraw pen from skin and THEN release the button. Do not press the green button without a needle attached.
12
Note: Do not move the pen after inserting. If the green injection button cannot be pressed down or stops before the "●0", see below under "Troubleshooting". Slowly remove the pen from the injection site by pulling the pen needle straight out. You may have slight bleeding, this is normal. Do not rub the injection site. If slight bleeding occurs, press a cotton ball or gauze pad to the injection site as required. You may also cover the area with a small adhesive bandage. Step 7 Remove the pen needle Caution: To prevent needle stick injury, follow this step carefully. Carefully place the outer needle cap back on the needle. Then carefully press on the outer needle cap until it snaps into place and is secure.
Unscrew the capped needle. To unscrew the capped needle, squeeze the cap at the base against the needle, then turn it 8 or more times before gently pulling until the capped needle comes off. Note: Do not push down on the outer needle cap while unscrewing the needle.
Note: You should see a gap widening between the outer needle cap and the pen as you unscrew the needle.
13
Step 8 After your injection Firmly replace the pen cap onto the Eladynos pen. Keep the cap on your pen between injections.
Troubleshooting What should I do if the needle is bent? • Carefully remove the bent needle and follow Step 2 to attach a new needle to the pen. The pen needle has a visible portion which goes into your skin and there is a hidden inner needle portion that goes into the pen's septum. • Review the parts of the pen needle, paying close attention to the inner needle portion. The visible portion of the needle may look straight, but the inner needle can become bent when attaching the needle to the pen. • Be sure to keep the entire pen needle straight when attaching it to the pen to avoid bending the inner needle. What should I do if liquid does not come out of the needle tip when testing the pen on Day 1? • If you do not see liquid come out of the needle, the pen setup is not complete. The needle may be blocked, bent or improperly attached. • Follow Step 2 to attach a new needle to the pen and repeat Step 3 "Testing an Eladynos pen prior to first injection". • If you still do not see a drop of liquid contact your pharmacist, nurse or doctor. What should I do if I cannot turn the white dose knob to set the Eladynos pen to "●80"? • There is not enough medicine in the pen to give you a full dose. You will need to get a new pen. What should I do if the green injection button is difficult to press? • If the green injection button cannot be pressed down or stops before the "●0" in the dose display window, the new pen test is not complete. The needle may be blocked or improperly attached. • Follow Step 2 to attach a new needle to the pen. • If the green injection button still cannot be pressed down or stops before the "●0" is in the display window, contact your pharmacist, nurse or doctor.
14
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Eladynos and immediately contact your doctor or go to the emergency centre if you experience the following symptoms (severe allergic reaction): swelling of the face or tongue; wheezing and trouble breathing; hives, itching and flushed skin; severe vomiting or diarrhea; lightheadedness or loss of consciousness (frequency not known). These symptoms may be serious and potentially life-threatening.
4
Other side effects can occur with the following frequencies: Very common (may affect more than 1 in 10 people) • increase in calcium level seen in urine tests • dizziness – see section 2 "Warnings and Precautions" Common (may affect up to 1 in 10 people) • increase in calcium level seen in blood tests • increase in uric acid level seen in blood tests • headache • palpitations, increased heartbeat • increase in blood pressure • abdominal pain • constipation, diarrhoea • feeling sick (nausea), vomiting • weakness, tiredness, feeling unwell • injection site reactions such as bruising, rash and pain • pain in bones, joints, hands, feet or back • muscle spasms (back and legs) • difficulty sleeping • kidney stones • itching, rash Uncommon: may affect up to 1 in 100 people • allergic reactions • feeling bloated • pain • feeling dizzy or lightheaded on standing or sitting up because of a drop in blood pressure Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow card Scheme, website: http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Eladynos
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and pen after EXP. The expiry date refers to the last day of that month. Before first use, store in a refrigerator (2 °C-8 °C). Do not freeze. Avoid placing the pens close to the ice compartment of the refrigerator to prevent freezing. Do not use Eladynos if it is, or has been, frozen. After first use, store below 25 °C and discard after 30 days. Eladynos may only be stored at room temperature (below 25 °C) for 30 days.
5
Note the date of Day 1 in the space provided on the carton. Day 1 is the date of first use or the date the pen was removed from the refrigerator. This is to ensure you do not use the pen for more than 30 consecutive days or store the pen for longer than 30 days. After 30 days, throw away your pen in accordance with local requirements, even if it still contains unused medicine. • • •
Dispose of your old pen prior to opening a new Eladynos pen, to avoid potential confusion. Do not store the pen with the needle attached. Do not use this medicine if the solution is cloudy, coloured or contains particles.
Do not throw away any medicines or needles via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Eladynos contains • The active substance is abaloparatide. Each dose of 40 microliters contains 80 micrograms of abaloparatide. Each pre-filled pen contains 3 mg of abaloparatide in 1.5 mL of solution (corresponding to 2 milligrams per mL). • The other ingredients are: phenol water for injections sodium acetate trihydrate (See section 2 "Eladynos contains Sodium") and acetic acid (both for pH adjustment) What Eladynos looks like and contents of the pack Eladynos is a colourless and clear solution for injection (injection). It is supplied in a carton containing one or three pre-filled multi-dose pens with 30 doses. Not all pack sizes may be available. Marketing Authorisation Holder Theramex Ireland Limited 3rd Floor, Kilmore House, Park Lane, Spencer Dock, Dublin 1 D01 YE64 Ireland Manufacturer Theramex Poland Sp. z o. o. Amsterdam Building, ul. Poleczki 35, 02-822 Warszawa Poland This leaflet was last revised in March 2024.
6
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu ———————————————————————————————————————–Instructions for Use Do not inject Eladynos until you or your caregiver receive training from a doctor, nurse or pharmacist on
Eladynos 80 microgram solution for injection in pre-filled pen comes as injection containing 80mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Eladynos 80 microgram solution for injection in pre-filled pen is abaloparatide.
This leaflet reproduces the patient information leaflet approved for Eladynos 80 microgram solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).
Posology
The recommended dose is 80 micrograms once daily.
The maximum total duration of treatment with abaloparatide should be 18 months (see sections 4.4 and 5.1).
Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
Following cessation of abaloparatide therapy, patients may be continued on other osteoporosis therapies such as bisphosphonates.
Missed dose
If a patient forgets or cannot administer their dose at the usual time, it can be injected within 12 hours of the normally scheduled time. Patients should not administer more than one injection in the same day and should not try to make up for a missed dose.
Special populations
Elderly patients
Dose adjustment based on age is not required (see section 5.2).
Renal impairment
Abaloparatide must not be used in patients with severe renal impairment including patients with end-stage renal disease (see section 4.3). In patients with mild to moderate renal impairment, dose-based adjustment is not required (see section 5.2).
Hepatic impairment
No data are available in patients with impaired hepatic function. Dose adjustment is not required for these patients, as it is unlikely that hepatic impairment will have a significant effect on abaloparatide exposure (see section 5.2).
Paediatric population
Abaloparatide should not be used in children and adolescents less than 18 years because of safety concerns (see section 5.3).
Method of administration
For subcutaneous use only.
The first injection(s) administered by the patient or caregiver should be performed under the guidance of an appropriately qualified health care professional (see section 4.4). Patients and/or caregivers should be trained in the subcutaneous administration of abaloparatide (see section 6.6). A detailed instruction for use is included in each pack to instruct patients on the correct use of the injection pen.
Abaloparatide should be injected in the lower abdomen. The site of the injection should be rotated every day. Injections should be administered at approximately the same time every day.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Pregnancy and breast-feeding (see section 4.6)
- Women of childbearing potential (see sections 4.6 and 5.3)
- Pre-existing hypercalcaemia
- Severe renal impairment (see sections 4.2 and 5.2)
- Unexplained elevations of serum alkaline phosphatase
- Patients with known risks for osteosarcoma such as those who have received prior external beam or implant radiation therapy involving the skeleton (see section 5.3)
- Patients with skeletal malignancies or bone metastases
Orthostatic hypotension and increased heart rate
Orthostatic hypotension and transient episodes of increase in heart rate may occur with abaloparatide, typically within 4 hours of injection. Symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. The first injection(s) of abaloparatide should be performed under the guidance of an appropriately qualified health care professional who may observe the patient during the first hour after injection. Abaloparatide should always be administered where the patient can sit or lie down if necessary.
Abaloparatide may have vasodilating effect on vascular smooth muscle and positive chronotropic/inotropic effects on cardiac muscle. Individual benefit risk assessment is important. Blood pressure, cardiac status and ECG should be assessed prior to beginning treatment with abaloparatide. Patients with cardiac disease should be monitored for worsening of their disease. If severe orthostatic hypotension or severe cardiovascular symptoms occur, the treatment should be discontinued.
Hypercalcaemia
In normocalcaemic patients, transient elevations of serum calcium concentrations have been observed following abaloparatide injection. Serum calcium concentrations reach a maximum at approximately 4 hours and return to baseline by 24 hours after each dose. Therefore, if blood samples for serum calcium measurements are taken, this should be done approximately 24 hours after the most recent injection. Routine calcium monitoring during therapy is not required in patients without additional risk factors for hypercalcaemia.
Hypercalciuria and urolithiasis
Abaloparatide may cause hypercalciuria. It is unknown whether abaloparatide may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.
Duration of treatment
The maximum total duration of treatment with abaloparatide should be 18 months. Studies in rats indicate an increased incidence of osteosarcoma with long-term administration of abaloparatide (see section 5.3).
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium free'.
No dedicated clinical drug-drug interaction studies have been performed with abaloparatide. The interaction potential of abaloparatide is regarded low considering its pharmacokinetic properties.
There is no data on efficacy of abaloparatide in patients with prior or concomitant bisphosphonate or glucocorticoid treatment.
Concomitant use of vasoactive medicinal products may predispose to orthostatic hypotension since the blood pressure lowering effect of abaloparatide may be increased, see section 4.4.
Sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because abaloparatide has been shown to increase serum calcium, it should be used with caution in patients taking digitalis.
This medicine is not indicated in women of childbearing potential. It is not to be used in women who are, or may be, pregnant or breast-feeding (see sections 4.1 and 4.3).
Pregnancy
Eladynos is contraindicated during pregnancy (see section 4.3).
Breast-feeding
It is unknown whether abaloparatide is excreted in human milk. A risk to the newborns/infants cannot be excluded. Eladynos is contraindicated during breast-feeding (see section 4.3).
Fertility
No data are available on the effect of abaloparatide on human fertility. Studies in rats with abaloparatide have shown no effects on male fertility (see section 5.3).
Abaloparatide has no or negligible influence on the ability to drive and use machines. Transient orthostatic hypotension or dizziness may occur following administration of abaloparatide (see section 4.8). These patients should refrain from driving or the use of machines until symptoms have subsided.
Summary of the safety profile
The most commonly reported adverse drug reactions in patients treated with abaloparatide in the ACTIVE study were hypercalciuria (15.6%), dizziness (11.1%), back pain (8.6%), nausea (8.5%), headache (8.5%), arthralgia (8.4%), hypertension (6.8%), injection site reaction (6.2%), and palpitations (5.6%).
Tabulated list of adverse reactions
Of patients in the abaloparatide ACTIVE study, 90.3% of the abaloparatide patients and 88.4% of the placebo patients reported at least 1 adverse event.
The adverse reactions associated with the use of abaloparatide in osteoporosis in the ACTIVE study and in postmarketing exposure are summarised in the table below. The following MedDRA convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1 000), very rare (<1/10 000), and frequency not known (cannot be estimated from the available data).
Table 1 – Tabulated list of adverse reactions
Immune system disorders
Uncommon: Hypersensitivity
Frequency not known: Anaphylactic reaction
Metabolism and nutrition disorders
Common: Hypercalcaemia, hyperuricaemia
Psychiatric disorders
Common: Insomnia
Nervous system disorders
Very common: Dizziness
Common: Headache
Cardiac disorders
Common: Palpitations, tachycardia
Vascular disorders
Common: Hypertension
Uncommon: Orthostatic hypotension
Gastrointestinal disorders
Common: Nausea, abdominal pain, constipation, diarrhoea, vomiting
Uncommon: Abdominal distension
Skin and subcutaneous tissue disorders
Common: Pruritus, rash
Musculoskeletal and connective tissue disorders
Common: Back pain, arthralgia, pain in extremity, muscle spasms (back and legs), bone pain
Renal and urinary disorders
Very common: Hypercalciuria
Common: Nephrolithiasis
General disorders and administration site conditions
Common: Injection site reaction, fatigue, asthenia, malaise
Uncommon: Pain
Description of selected adverse reactions
Increased heart rate
In the QT study, the placebo-adjusted mean heart rate increase was 14.5 beats per minute (bpm) 15 minutes after administration. This increase in heart rate was most prominent during the first hour post dose but was seen up to 6 hours in some subjects.
In the ACTIVE study, heart rate was measured one hour post dose of every study visit, with median heart rate increase from pre-dose of 14 bpm in abaloparatide treated patients as compared to 7 bpm in placebo treated patients. Patients with >20 bpm increase in heart rate at 1 hour after the first dose were more likely to experience palpitations and/or increases in heart rate >20 bpm during subsequent treatment. Adverse reactions of tachycardia and sinus tachycardia were reported in 1.6% of patients receiving abaloparatide and 0.4% of patients in the placebo group.
Orthostatic hypotension
In women with postmenopausal osteoporosis, adverse reactions of orthostatic hypotension were reported in 1% of patients receiving abaloparatide and 0.6% of patients in the placebo group.
Injection site reactions
Abaloparatide can cause injection site reactions including injection site bruising, erythema, haemorrhage, hypersensitivity, pain, rash, and swelling. The overall incidence in the abaloparatide arm was 5.3% compared to 4.0% in the placebo group.
Laboratory findings
Serum calcium
Abaloparatide can cause transient increases in serum calcium levels measured 4 hours post-dose. The overall incidence of hypercalcaemia, defined as albumin-corrected serum calcium ≥2.67 mmol/L (or ≥10.7 mg/dL) in the abaloparatide arm was higher (3.3%) compared to the placebo group (0.4%).
Serum uric acid
Abaloparatide increased serum uric acid concentrations. In the ACTIVE study, 25% of patients in the abaloparatide group had normal baseline uric acid concentrations which were increased above the normal range at post-baseline, compared with 5% in the placebo group.
Hypercalciuria and urolithiasis
In the clinical trial of women with postmenopausal osteoporosis, the overall incidence of urine calcium: creatinine ratio >0.00113 mmol/µmol (or >400 mg/g) was higher with abaloparatide than with placebo (20% vs 15%, respectively). Urolithiasis was reported in 1.4% of abaloparatide-treated patients and 1.2% of placebo-treated patients.
Immunogenicity
Of the patients receiving abaloparatide for 18 months, 42.9% developed anti-abaloparatide antibodies and 28.5% developed in vitro neutralising antibodies. Formation of anti-abaloparatide antibodies is associated with increased clearance of abaloparatide. These changes in clearance could be related to anti-abaloparatide antibodies interfering with the accurate measurement of abaloparatide plasma concentrations. Compared to antibody negative patients, no clinically relevant differences in safety or efficacy were observed for patients who were antibody positive or who were positive for in vitro neutralising antibodies.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Signs and symptoms
In clinical trials, abaloparatide has been administered subcutaneously in single doses of up to 320 micrograms and in repeated doses of up to 120 micrograms/day for 7 days. The primary dose-limiting adverse effect was postural dizziness.
The effects of overdose that might be expected include transient hypecalciuria, hypercalcaemia, nausea, vomiting, dizziness, palpitations, orthostatic hypotension and headache.
In the clinical programme with an earlier pen design, accidental overdose was reported in a patient who received 400 micrograms in one day (5 times the recommended clinical dose). The patient experienced asthenia, headache, nausea, and vertigo. Serum calcium was not assessed on the day of the overdose, but on the following day the patient's serum calcium was within the normal range.
Overdose management
There is no specific antidote for abaloparatide. Treatment of suspected overdose may include transitory discontinuation of treatment, monitoring of serum calcium and implementation of appropriate supportive measures, such as hydration.
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Eladynos 80 microgram solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.